Viewray Inc (NASDAQ:VRAY) has received an average recommendation of “Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $11.90.
Several research firms have recently issued reports on VRAY. BidaskClub lowered Viewray from a “hold” rating to a “sell” rating in a report on Friday, June 8th. Cantor Fitzgerald reissued a “buy” rating and set a $13.00 target price on shares of Viewray in a report on Friday, May 11th. ValuEngine raised Viewray from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Mizuho reissued a “buy” rating and set a $12.00 target price on shares of Viewray in a report on Thursday, April 19th.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PEAK6 Investments L.P. acquired a new stake in shares of Viewray during the 4th quarter worth $148,000. MetLife Investment Advisors LLC bought a new stake in shares of Viewray during the 4th quarter worth $148,000. Barclays PLC lifted its position in shares of Viewray by 416.1% during the 1st quarter. Barclays PLC now owns 25,041 shares of the company’s stock worth $161,000 after buying an additional 20,189 shares during the last quarter. California Public Employees Retirement System bought a new stake in shares of Viewray during the 4th quarter worth $317,000. Finally, UBS Group AG lifted its position in shares of Viewray by 1,100.6% during the 1st quarter. UBS Group AG now owns 35,525 shares of the company’s stock worth $228,000 after buying an additional 32,566 shares during the last quarter. 83.36% of the stock is currently owned by institutional investors.
Shares of VRAY traded up $0.21 during trading hours on Friday, hitting $7.67. 681,800 shares of the company were exchanged, compared to its average volume of 650,887. The firm has a market cap of $535.21 million, a P/E ratio of -7.38 and a beta of 0.56. Viewray has a fifty-two week low of $4.40 and a fifty-two week high of $10.64. The company has a debt-to-equity ratio of 0.77, a quick ratio of 3.04 and a current ratio of 3.79.
Viewray (NASDAQ:VRAY) last released its earnings results on Thursday, May 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.09. The company had revenue of $26.19 million for the quarter, compared to analyst estimates of $15.50 million. Viewray had a negative return on equity of 1,375.57% and a negative net margin of 83.09%. Viewray’s quarterly revenue was up 2029.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.54) EPS. research analysts predict that Viewray will post -0.65 earnings per share for the current fiscal year.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.